Why is 10 % dextrose (D10) administered to an intensive care unit (ICU) patient with end‑stage renal disease (ESRD)?

D10 Administration in ICU ESRD Patients

D10 (10% dextrose) is given to ICU patients with end-stage renal disease primarily to prevent hypoglycemia when insulin is administered for hyperkalemia treatment, and secondarily to prevent rebound hypoglycemia when discontinuing concentrated dextrose infusions or when enteral nutrition is interrupted.

Primary Indication: Hypoglycemia Prevention During Hyperkalemia Treatment

ESRD patients are at exceptionally high risk for insulin-induced hypoglycemia when treated for hyperkalemia because:

• Impaired renal clearance (CrCl <30 mL/min or dialysis-dependent) prolongs insulin action
• Lower baseline glucose levels are common in this population
• Insulin doses of 10 units with only a single dextrose bolus result in hypoglycemia rates of 20% in ESRD patients 1

Evidence-Based Protocol

The most effective approach combines D50 bolus with D10 infusion:

• Give 50 mL of D50 (25g) IV push with insulin administration
• Immediately start 250 mL of D10 infused over 2 hours 1
• This dual-dextrose strategy reduces hypoglycemia rates from 20% to 6% in ESRD patients (p=0.003) 1

The continuous D10 infusion addresses the critical problem that hypoglycemia commonly occurs 60-240 minutes after insulin administration—well beyond the effect of a single dextrose bolus 1.

Dosing Considerations by Patient Risk

For ESRD patients with pre-treatment glucose ≤250 mg/dL:

• Reduce insulin dose from 10 to 5 units
• Administer both D50 bolus AND D10 infusion 1

For patients with baseline glucose <110 mg/dL or non-diabetic status:

• 50g dextrose significantly reduces hypoglycemia compared to 25g 2
• D10 infusion becomes even more critical 3

Secondary Indication: Prevention of Rebound Hypoglycemia

When discontinuing concentrated dextrose infusions (commonly used in ICU for parenteral nutrition or glycemic management), the FDA label explicitly recommends transitioning to 5% or 10% dextrose to avoid rebound hypoglycemia 4.

Mechanism

Prolonged concentrated dextrose infusions stimulate endogenous insulin secretion. Abrupt cessation can cause:

• Persistent hyperinsulinemia
• Precipitous glucose drop
• Severe hypoglycemia

D10 provides a bridge that allows gradual insulin level normalization while maintaining adequate glucose supply.

Tertiary Indication: Enteral Nutrition Interruption

When tube feeding is interrupted in ICU patients receiving basal insulin, guidelines recommend starting IV 10% dextrose at 50 mL/hour to prevent hypoglycemia 5. This is particularly relevant in ESRD patients who:

• Have prolonged insulin action
• Cannot rapidly clear exogenous insulin
• Are at higher baseline mortality risk (hospital mortality 49% vs 32% in non-ESRD septic patients) 6

Critical Monitoring Requirements

Blood glucose monitoring must be:

• Every 60 minutes during glycemic instability 7
• Continued for at least 240 minutes post-insulin administration 1
• More frequent (every 2-4 hours minimum) during D10 infusion 5

Common Pitfalls to Avoid

1. Single dextrose bolus only: Inadequate for ESRD patients—hypoglycemia occurs hours later 1
2. Premature D10 discontinuation: Continue for full 2 hours minimum 1
3. Inadequate glucose monitoring: Must extend beyond initial 60 minutes 3
4. Ignoring baseline glucose: Patients with glucose <110 mg/dL need more aggressive dextrose supplementation 2, 3

Hyperglycemia Risk

D10 infusion does cause transient hyperglycemia more frequently than lower dextrose doses, but this does not persist at 240 minutes and is clinically preferable to hypoglycemia in critically ill ESRD patients 2. The 2024 Critical Care Medicine guidelines recommend avoiding intensive glucose targets and accepting glucose levels up to 10 mmol/L (180 mg/dL) to minimize hypoglycemia risk 7.